urologytimes

Ashish M. Kamat, MD, MBBS, FACS, on why pathology accuracy drives every MIBC treatment decision

On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review. In this video, recorded at the 41st Annual Congress of the European Association of ...
urologytimes

Urologist explains science behind HA penile injections

Alex Tatem, MD, explains that hyaluronic acid penile injections add temporary, measurable girth by safely distributing a reversible filler within soft tissue, though outcomes depend heavily on ...
urologytimes

GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance

The Genomic Prostate Score (GPS) is being validated in the ProtecT trial to predict prostate cancer progression and treatment outcomes. ProtecT is a landmark phase 3 trial with over 1600 men, ...
urologytimes

ORIC-944 shows promise in combination with ARPIs for mCRPC

ORIC-944 demonstrated significant anti-tumor activity and tolerability in combination with ARPIs in mCRPC patients. The phase 1b trial showed notable PSA and ctDNA reductions across all ORIC-944 dose ...
urologytimes

FDA approves Altaviva device for urge urinary incontinence

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
urologytimes

AI and prostate cancer: Balancing hope and caution

AI tools like PathomIQ can predict prostate cancer metastasis by analyzing whole-slide images, independent of Gleason scores and gene expression profiling. Current AI applications in prostate cancer ...
urologytimes

Enzalutamide shows improved relative efficacy over darolutamide in mHSPC

Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death and castration resistance compared to darolutamide plus ADT in mHSPC patients. The MAIC analysis provided a ...
urologytimes

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...
urologytimes

Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

NCCN guideline-recommended treatments significantly reduce prostate cancer mortality compared to other causes, even in high-risk patients. The study involved 135,636 Swedish patients, with 46% ...
urologytimes

FDA approves integrated sacral neuromodulation system for urinary urge incontinence

Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...
urologytimes

From prep to follow-up: Key considerations for administering onabotulinumtoxinA

Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, antibiotic use, ...
urologytimes

FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...